ImmunoGen announced that the European Medicines Agency has accepted the Marketing Authorization Application for mirvetuximab soravtansine for the treatment of patients with folate receptor alpha-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on IMGN:
- Biotech Alert: Searches spiking for these stocks today
- ImmunoGen ‘should rank high on list’ of possible M&A targets, says Guggenheim
- Cellectar Biosciences appoints Yoon, Nanduri as VPs
- e.l.f. Beauty upgraded, AutoZone downgraded: Wall Street’s top analyst calls
- Oppenheimer starts Sutro Biopharma at Outperform, sees 200% possible upside